Cargando…
Remodeling tumor microenvironment by liposomal codelivery of DMXAA and simvastatin inhibits malignant melanoma progression
Anti-angiogenic therapies for melanoma have not yet been translated into meaningful clinical benefit for patients, due to the development of drug-induced resistance in cancer cells, mainly caused by hypoxia-inducible factor 1α (HIF-1α) overexpression and enhanced oxidative stress mediated by tumor-a...
Autores principales: | Rauca, Valentin-Florian, Patras, Laura, Luput, Lavinia, Licarete, Emilia, Toma, Vlad-Alexandru, Porfire, Alina, Mot, Augustin Catalin, Rakosy-Tican, Elena, Sesarman, Alina, Banciu, Manuela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585864/ https://www.ncbi.nlm.nih.gov/pubmed/34764332 http://dx.doi.org/10.1038/s41598-021-01284-5 |
Ejemplares similares
-
Combination therapy of simvastatin and 5, 6-dimethylxanthenone-4-acetic acid synergistically suppresses the aggressiveness of B16.F10 melanoma cells
por: Rauca, Valentin-Florian, et al.
Publicado: (2018) -
Active Tumor-Targeting Nano-formulations Containing Simvastatin and Doxorubicin Inhibit Melanoma Growth and Angiogenesis
por: Negrea, Giorgiana, et al.
Publicado: (2022) -
Liposomal simvastatin sensitizes C26 murine colon carcinoma to the antitumor effects of liposomal 5‐fluorouracil in vivo
por: Luput, Lavinia, et al.
Publicado: (2020) -
Overcoming Intrinsic Doxorubicin Resistance in Melanoma by Anti-Angiogenic and Anti-Metastatic Effects of Liposomal Prednisolone Phosphate on Tumor Microenvironment
por: Licarete, Emilia, et al.
Publicado: (2020) -
In Vivo Double Targeting of C26 Colon Carcinoma Cells and Microenvironmental Protumor Processes Using Liposomal Simvastatin
por: Luput, Lavinia, et al.
Publicado: (2018)